Neoplasm by Morphology

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Complete hematologic response (CHR) and ma… (full text at CIViC)

PMID 21865346 · Cortes et al., 2011 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In an in vitro study, a Ba/F3-p210BCR-ABL1 cell line was ENU-mutated and exposed to graded concentrations of imatinib, nilotinib or dasatinib to identify resistance mutations. The L384M mutation in th… (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Among 115 patients with mutational analysi… (full text at CIViC)

PMID 21865346 · Cortes et al., 2011 · Open in CIViC

This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC)

PMID 22371878 · Khoury et al., 2012 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Among 115 patients with mutational analysi… (full text at CIViC)

PMID 21865346 · Cortes et al., 2011 · Open in CIViC

This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC)

PMID 22371878 · Khoury et al., 2012 · Open in CIViC

In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to dasatinib. This line showed a significant reduction in colony fo… (full text at CIViC)

PMID 26758680 · Testoni et al., 2016 · Open in CIViC

In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to imatinib. This line showed a significant reduction in colony for… (full text at CIViC)

PMID 26758680 · Testoni et al., 2016 · Open in CIViC

In this study, patients on imatinib monotherapy were monitored for ABL1 kinase domain variants in BCR-ABL1 fusions amplified from peripheral blood RNA. Among 64 patients initially in late-chronic phas… (full text at CIViC)

PMID 12623848 · Branford et al., 2003 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In phase 1, dose-escalation trial 141 patients with chronic-phase chronic myeloid leukemia (CML) and 9 patients with accelerated-phase CML who had previously taken at least two ATP-competitive tyrosin… (full text at CIViC)

PMID 31826340 · Hughes et al., 2019 · Open in CIViC

In an in vitro study, stochastic mutations were introduced into the ABL1 region of a stably expressed p210 BCR-ABL fusion in Ba/F3 cells using N-ethyl-N-nitrosourea mutagenesis. Resulting clones were … (full text at CIViC)

PMID 16772610 · Bradeen et al., 2006 · Open in CIViC

In this retrospective study, imatinib-resistant or -intolerant patients, with chronic phase CML and BCR-ABL fusions, were treated with bosutanib monotherapy. Among 115 patients with mutational analysi… (full text at CIViC)

PMID 21865346 · Cortes et al., 2011 · Open in CIViC

This was a retrospective study of dasatinib and/or nilotinib-resistant or -intolerant patients pretreated with imatinib aimed at evaluating the efficacy of bosutanib monotherapy. All patients had chro… (full text at CIViC)

PMID 22371878 · Khoury et al., 2012 · Open in CIViC

In this phase 1/2, open‐label, two‐part study, advanced leukemia patients with prior treatment failure (accelerated‐phase [AP, n = 79] chronic myeloid leukemia [CML], blast‐phase [BP, n = 64] CML, acu… (full text at CIViC)

PMID 26040495 · Gambacorti-Passerini et al., 2015 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In this phase II multinational study, patients with accelerated phase CML and BCR-ABL fusions were treated with dasatinib monotherapy. Response rate among 60 imatinib-resistant patients with BCR-ABL m… (full text at CIViC)

PMID 17264298 · Guilhot et al., 2007 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

In a retrospective study of 1084 imatinib-resistant or -intolerant, chronic myeloid leukemia (chronic-phase) patients, patients with a mutation in the ABL1 portion of the BCR-ABL gene fusion were asso… (full text at CIViC)

PMID 19779040 · Müller et al., 2009 · Open in CIViC

Four lung adenocarcinoma cell lines were studied with mutations in ABL1 or ABL2. Sensitivity to imatinib or dasatinib treatment was measured by reduction in colony formation in response to treatment. … (full text at CIViC)

PMID 26758680 · Testoni et al., 2016 · Open in CIViC

Four lung adenocarcinoma cell lines were studied with mutations in ABL1 or ABL2. Sensitivity to imatinib or dasatinib treatment was measured by reduction in colony formation in response to treatment. … (full text at CIViC)

PMID 26758680 · Testoni et al., 2016 · Open in CIViC

ActA level was measured in serum and plasma samples of 64/87 lung adenocarcinoma patients and 46/66 age- and gender-matched controls (ELISA). ActA Levels were higher in patients than in controls and w… (full text at CIViC)

PMID 26950277 · Hoda et al., 2016 · Open in CIViC

This study performed exome sequencing on 55 DLBCL tumor samples and identified several significantly mutated genes including ACTB.

PMID 22343534 · Lohr et al., 2012 · Open in CIViC

High expression of ACTL6A has been shown to be associated with resistance to cisplatin in multiple cancer types. In vitro experiments using A549 and H1299 lung cancer cell lines showed that overexpres… (full text at CIViC)

PMID 33408251 · Xiao et al., 2021 · Open in CIViC

ACTL6A plays a role in DNA damage repair by maintaining integrity of the SWI/SNF complex, and is associated with resistance to cisplatin. Results from cell viability and survival assays showed that tr… (full text at CIViC)

PMID 33408251 · Xiao et al., 2021 · Open in CIViC

Sequencing (whole genome or exome) was performed on a series of 26 pediatric patients (1.7 to 13.6 years old), 7 had missense mutations in ACVR1. Two patients with G328E mutation were identified. This… (full text at CIViC)

PMID 24705252 · Taylor et al., 2014 · Open in CIViC

In a study sequencing 61 patients (median age 6.3) with diffuse intrinsic pontine glioma (DIPG), 12 variants affecting ACVR1 were observed. Five patients had G328V within the kinase domain. The ACVR1 … (full text at CIViC)

PMID 24705254 · Buczkowicz et al., 2014 · Open in CIViC

It has been reported that recurrent activating somatic mutations (R206H, R258G, G328E/V/W, G356D) in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, are in 21% (11/52)… (full text at CIViC)

PMID 24705252 · Taylor et al., 2014 · Open in CIViC

It has been reported that recurrent activating somatic mutations (R206H, R258G, G328E/V/W, G356D) in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, are in 21% (11/52)… (full text at CIViC)

PMID 24705252 · Taylor et al., 2014 · Open in CIViC

This mutation is found to be present in about 33% of diffuse intrinsic pontine glioma along with 6 other recurrent heterozygous somatic non-synonymous mis-sense mutations in ACVR1. There lacks evidenc… (full text at CIViC)

PMID 26776312 · Pacifici et al., 2016 · Open in CIViC

It has been reported that recurrent activating somatic mutations (R206H, R258G, G328E/V/W, G356D) in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, are in 21% (11/52)… (full text at CIViC)

PMID 24705252 · Taylor et al., 2014 · Open in CIViC

The authors used whole exome sequencing on 39 midline pediatric high-grade astrocytomas (pHGAs) and identified 5 with mutations in ACVR1, with 2 occurring at G328 (G328V and G328E). The authors state … (full text at CIViC)

PMID 24705250 · Fontebasso et al., 2014 · Open in CIViC

Sequencing of 39 pediatric midline high-grade astrocytomas identified 5 patients with ACVR1 mutations. The authors identified an increase in endogenous phospho-SMAD1/5/8 signal in diffuse intrinsic po… (full text at CIViC)

PMID 24705250 · Fontebasso et al., 2014 · Open in CIViC

Analysis of 127 paediatric high grade gliomas (HGGs) identified recurrent mutations in ACVR1 exclusively in DIPG. ACVR1 mutations were found in 18 of 57 DIPG tumours (32%) and none of 70 non-brainstem… (full text at CIViC)

PMID 24705251 · Wu et al., 2014 · Open in CIViC

It has been reported that recurrent activating somatic mutations (R206H, R258G, G328E/V/W, G356D) in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, are in 21% (11/52)… (full text at CIViC)

PMID 24705252 · Taylor et al., 2014 · Open in CIViC